A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Clinical trial NCT04736706 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04736706
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-14
- Primary completion
- 2026-02-04
- Enrollment
- 1854
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.